Cardiac events and dynamic echocardiographic and electrocardiogram changes following osimertinib treatment in lung cancer

Cardiac events and dynamic echocardiographic and electrocardiogram changes following osimertinib treatment in lung cancer

Osimertinib is first-line treatment for epidermal growth factor (EGFR)-mutated non-small cell lung cancer (NSCLC) and has been associated with cardiotoxicity. However, the nature of cardiac remodeling and associated risk factors remains incompletely understood. Retrospective analysis of NSCLC patien...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän: Jonathan N. Le, Jordan O. Gasho, Olivia Peony, Asneh Singh, Katrina D. Silos, Sungjin Kim, Anthony T. Nguyen, Mitchell Kamrava, Amin Mirhadi, Behrooz Hakimian, Karen L. Reckamp, Kamya Sankar, Raymond H. Mak, Andriana P. Nikolova, Katelyn M. Atkins
Materialtyp: Artikel
Språk:English
Publicerad: Frontiers Media S.A. 2024-12-01
Serie:Frontiers in Cardiovascular Medicine
Ämnen:
osimertinib
lung cancer
cardiac toxicity
echocardiogram
EGFR
Länkar:https://www.frontiersin.org/articles/10.3389/fcvm.2024.1485033/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2024.1485033/full

Liknande verk